This study is for caregivers of young children with sickle cell disease and adolescents with sickle cell disease who are currently prescribed hydroxyurea and are receiving care at one of the study sites. The study will assess retention and engagement during a pilot randomized control trial comparing video directly observed therapy (VDOT) to attention control. We also hope to understand more about patient and family preferences longer-term adherence monitoring and intervention. Participants will use an electronic adherence monitor (provided by the study team) to measure how often they are taking their hydroxyurea. Participants will also be asked to complete questionnaires throughout the study period to provide information about their expectations for, experience with, and satisfaction with the study materials.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Retention Rate
Timeframe: throughout the study at various timepoints after enrollment including: after approximately 30-90 days, 210 days, and 390 days
Sustained Engagement
Timeframe: Throughout the intervention period, which will take place from approximately 30 days after enrollment to 210 days after enrollment
Electronic Adherence
Timeframe: throughout the study at various timepoints after enrollment including: after approximately 30-90 days, 210 days, and 390 days